Complement inhibition with an anti-C5 monoclonal antibody prevents hyperacute rejection in a xenograft heart transplantation model

Transplantation

Volumn 68, Issue 11, 1999, Pages 1643-1651

  Wang, Hao ^a   Rollins, Scott A ^d   Gao, Zuhua ^c   Garcia, Bertha ^a   Zhang, Zheng ^b   Xing, Jingjing ^c   Li, Lan ^d   Kellersmann, Richard ^a   Matis, Louis A ^d   Zhong, Robert ^a,b,c  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LONDON HEALTH SCIENCES CENTRE   (Canada)

^c ROBARTS RESEARCH INSTITUTE   (Canada)

^d ALEXION PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; COMPLEMENT COMPONENT C5; COMPLEMENT INHIBITOR; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COMPLEMENT INHIBITION; CONTROLLED STUDY; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION; XENOGRAFT;

EID: 0033572881     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199912150-00007     Document Type: Article

References (56)

1. Leventhal JR, Dalmasso AP, Cromwell JW, et al. Prolongation of cardiac xenografts survival by depletion of complement. Transplantation 1993; 55: 857.
2. Kroshus TJ, Rollins SA, Dalmasso AP, et al. Complement inhibition with an anti-C5 monoclonal antibody prevents acute cardiac tissue injury in an ex vivo model of pig-to-human xenotransplantation. Transplantation 1995; 60: 1194.
3. McCurry KR, Kooyman DL, Alvarado CG, et al. Human complement regulatory proteins protect swine-to-primate cardiac xenografts from humoral injury. Nat Med 1995; 1: 423.
4. Fodor WL, Williams BL, Matis LA, et al. Expression of a functional human complement inhibitor in a transgenic pig as a model for the prevention of xenogeneic hyperacute organ rejection. Proc Natl Acad Sci USA 1994; 91: 11153.
5. Kobayashi T, Taniguchi S, Ye Y, et al. Delayed xenograft rejection in C3-depleted discordant (pig-to-baboon) cardiac xenografts treated with cobra venom factor. Transplant Proc 1996; 28: 560.
6. Platt JL, Vercellotti GM, Dalmasso AP, et al. Transplantation of discordant xenografts: a review of progress. Immunol Today 1990; 11: 450.
7. Cozzi E, White DJG. The generation of transgenic pigs as potential organ donors for humans. Nat Med 1995; 1: 964.
8. Kroshus TJ, Bolman RM III, Dalmasso AP, et al. Expression of human CD59 in transgenic pig organs enhances organ survival in an ex vivo xenogeneic perfusion model. Transplantation 1996; 61: 1513.
9. Bhatti FNK, Schmoeckel M, Zaidi A, et al. Three-month survival of HDAFF transgenic pig hearts transplanted into primates. Transplant Proc 1999; 31: 958.
10. Schmoeckel M, Bhatti FNK, Zaidi A, et al. Orthotopic heart transplantation in a transgenic pig-to-primate model. Transplantation 1998; 65: 1570.
11. Schmoeckel M, Nollert G, Shahmohammadi M, et al. Prevention of hyperacute rejection by human decay accelerating factor in xenogeneic perfused working hearts. Transplantation 1996; 62: 729.
12. Storck M, Abendroth D, Prestel R, et al. Morphology of hDAF (CD55) transgenic pig kidneys following ex-vivo hemoperfusion with human blood. Transplantation 1997; 63: 304.
13. Pascher A, Poehlein C, Storck M, et al. Immunopathological observations after xenogeneic liver perfusions using donor pigs transgenic for human decay-accelerating factor. Transplantation 1997; 64: 384.
14. Johnson EM, Leventhal J, Dalmasso AP, et al. Inactivation of C3 and C5 prolongs cardiac xenograft survival and decreases leukocyte infiltration in a model of delayed xenograft rejection. Transplant Proc 1996; 28: 603.
15. Pruitt SK, Kirk AD, Bollinger RR, et al. The effect of soluble complement receptor type 1 on hyperacute rejection of porcine xenografts. Transplantation 1994; 57: 363.
16. Weisman HF, Bartow T, Leppo MK, et al. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 1990; 249: 146.
17. Kobayashi T, Taniguchi S, Neethling FA, et al. Delayed xenograft rejection of pig-to-baboon cardiac transplants after cobra venom factor therapy. Transplantation 1997; 64: 1255.
18. Taniguchi S, Kobayashi T, Neethling FA, et al. Cobra venom factor stimulates anti-α-galactose antibody production in baboons: implications for pig-to-human xenotransplantation. Transplantation 1996; 62: 678.
19. Mulligan MS, Schmid E, Beck-Schimmer B, et al. Requirement and role of C5a in acute lung inflammatory injury in rats. J Clin Invest 1996; 98: 503.
20. Platt JL. Complement. In: Platt JL, eds. Hyperacute xenograft rejection. Austin, Texas: R.G. Landes, 1995: 103.
21. Baldwin WM III, Pruitt SK, Brauer RB, et al. Complement in organ transplantation: contributions to inflammation, injury, and rejection. Transplantation 1995: 59: 797.
22. Dalmasso AP. Complement in the pathophysiology and diagnosis of human diseases. Crit Rev Clin Lab Sci 1986; 24: 123.
23. Yoshida Y, Kang K, Berger M, et al. Monocyte induction of IL-10 and down-regulation of IL-12 by iC3b deposited in ultraviolet-exposed human skin. J Immunol 1998; 161: 5873.
24. Marth T, Kelsall BL. Regulation of interleukin-12 by complement receptor 3 signaling. J Exp Med 1997; 185: 1987.
25. Vakeva AP, Agah A, Rollins SA, Matis LA, Li L, Stahl GL. Myocardial infarction and apoptosis after myocardial ischemia and reperfusion: role of the terminal complement components and inhibition by anti-C5 therapy. Circulation 1998; 97: 2259.
26. Wang Y, Hu Q, Madri JA, Rollins SA, Chodera A, Matis LA. Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. Proc Natl Acad Sci USA 1996; 93: 8563.
27. Wang Y, Rollins SA, Madri JA, Matis LA. Anti-CS monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease. Proc Natl Acad Sci USA 1995; 92: 8955.
28. Rinder CS, Rinder HM, Smith BR, et al. Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation. J Clin Invest 1995; 96: 1564.
29. Rollins SA, Matis LA, Springhorn JP, et al. Monoclonal antibodies directed against human C5 and C8 block complement-mediated damage of xenogeneic cells and organs. Transplantation 1995; 60: 1284.
30. Olfert ED, Cross BM, McWilliam AA. Responsibility for the care and use of experimental animals. In: Olfert ED, Cross BM, McWilliam AA, eds. Guide to the care and use of experimental animals, Vol. 1. Ottawa: Association of Universities and Colleges of Canada, 1993: 1.
31. Corry RJ, Winn HJ, Russell PS. Primary vascularized allograft of hearts in mice. Transplantation 1973; 16: 343.
32. Zhang Z, Zhu L, Quan D, et al. Pattern of liver, kidney, heart, and intestine allograft rejection in different mouse strain combinations. Transplantation 1996; 62: 1267.
33. Binder J, Lehmann M, Graser E, et al. The effect of nondepleting CD4 targeted therapy in presensitized rat recipients of cardiac allografts. Transplantation 1996; 61: 804.
34. Onodera K, Lehmann M, Akalin E, et al. Induction of "infectious" tolerance to MHC-incompatible cardiac allografts in CD4 mAb-treated sensitized rat recipients. J Immunol 1996; 157: 1944.
35. Good AH, Cooper DK, Malcolm AJ, et al. Identification of carbohydrate structures that bind human antiporcine antibodies: implications for discordant xenografting in humans. Transplant Proc 1992; 24: 559.
36. Cooper DK, Good AH, Koren E, et al. Identification of alpha-galactosyl and other carbohydrate epitopes that are bound by human anti-pig antibodies: relevance to discordant xenografting in man. Transpl Immunol 1993; 1: 198.
37. Perper RJ, Najarian JS. Experimental renal heterotransplantation. I. In widely divergent species. Transplantation 1966; 4: 377.
38. Gewurz H, Clark DS, Cooper MD, Varco RL, Good RA. Effect of cobra venom-induced inhibition of complement activity on allograft and xenograft rejection reactions. Transplantation 1967; 5: 1296.
39. Murphy HS, Shayman JA, Till GO, et al. Superoxide responses of endothelial cells to C5a and TNF-alpha: divergent signal transduction pathways. Am J Physiol 1992; 263: L51.
40. Platt JL, Dalmasso AP, Lindman BJ, et al. The role of C5a and antibody in the release of heparan sulfate from endothelial cells. Eur J Immunol 1991; 21: 2887.
41. Morgan BP. Effects of membrane attack complex of complement on nucleated cells. Curr Top Microbiol Immunol 1992; 178: 115.
42. Zhow XJ, Niesen N, Pawlowski I, et al. Prolongation of survival of discordant kidney xenografts by C6 deficiency. Transplantation 1990; 50: 896.
43. Brauer RB, Baldwin WM III, Daha MR, et al. Use of C6-deficient rat to evaluate the mechanism of hyperacute rejection of discordant cardiac xenografts. J Immunol 1993; 151: 7240.
44. Kobayashi T, Neethling FA, Taniguchi S, et al. Investigation of the anti-complement agents, FUT-175 and K76COOH, in discordant xenotransplantation. Xenotransplantation 1996; 3: 237.
45. Bach FH, Winkler H, Ferran C, Hancock WW, Robson SC. Delayed xenograft rejection. Immunol Today 1996; 17: 379.
46. Leventhal JR, Matas AJ, Sun LH, et al. The immunopathology of cardiac xenograft rejection in the guinea pig-to-rat model. Transplantation 1993; 56: 1.
47. Platt JL, Vercellotti GM, Lindman BJ, et al. Release of heparan sulfate from endothelial cells: implications for pathogenesis of hyperacute rejection. J Exp Med 1990; 171: 1363.
48. Miyagawa S, Hirose H, Shirakura R, et al. The mechanism of discordant xenograft rejection. Transplantation 1988; 46: 825.
49. Galili U. Anti-αgalactosyl (anti-gal) antibody damage beyond hyperacute rejection. In: Cooper DKC, Kemp E, Platt JL, White DJG, eds. Xenotransplantation: the transplantation of organs and tissues between species. Berlin: Springer, 1997: 95.
50. Hancock WW. Delayed xenograft rejection. World J Surg 1997; 21: 917.
51. Lin Y, Vandeputte M, Waer M, et al. Natural killer cell- and macrophage-mediated rejection of concordant xenografts in the absence of T and B cell responses. J Immunol 1997; 158: 5658.
52. Sandrin MS, Fodor WL, Mouhtouris E, et al. Enzymatic remodelling of the carbohydrate surface of a xenogenic cell substantially reduces human antibody binding and complement-mediated cytolysis. Nat Med 1995; 1: 1261.
53. + T cells. J Exp Med 1989; 170: 991.
54. Zhong R, Tucker J, Grant D, et al. Long-term survival and functional tolerance of baboon to monkey kidney and liver transplantation: a preliminary report. Transplant Proc 1996; 28: 762.
55. Waterworth PD, Cozzi E, Tolan MJ, et al. Pig-to-primate cardiac xenotransplantation and cyclophosphamide therapy. Transplant Proc 1997; 29: 899.
56. Davis EA, Jakobs F, Pruitt SK, et al. Overcoming rejection in pig-to-primate cardiac xenotransplantation. Transplant Proc 1997; 29: 938.